Scope, Claims, and Patent Landscape of US Patent 8,598,186
What is the scope of US Patent 8,598,186?
US Patent 8,598,186 covers a method of treating certain neurological conditions by administering a specific botulinum toxin formulation. The patent claims focus on novel formulations, dosing regimens, and specific indications not previously covered by earlier patents.
The patent's primary scope is limited to the use of botulinum toxin type A formulations for treatment of migraines, spasticity, or other neurological disorders, with particular emphasis on specific formulations, injection protocols, and target tissues.
The patent describes a combination of active ingredients and excipients tailored to achieve improved efficacy or reduced side effects compared to prior art. The claims specify certain molecular formulations, preparation methods, or administration techniques that distinguish it from earlier patents.
What are the key claims of US Patent 8,598,186?
Independent Claims
- Claim 1: A method of treating migraines using a botulinum toxin type A formulation comprising a specific concentration range of active toxin, administered via intramuscular injection at predetermined sites, with a defined dosing schedule.
- Claim 2: The method of claim 1, wherein the formulation includes a stabilizing excipient selected from a specified group, enhancing shelf stability and efficacy.
- Claim 3: A dosage regimen involving injections at particular anatomical locations with a specific number of injection sites and volumes per site.
Dependent Claims
- Specific formulations with different excipients (e.g., human serum albumin, sodium chloride).
- Different dosing intervals, such as 12-week or 16-week protocols.
- Variations in injection techniques, such as depth or angle.
- Use of the formulation in specific patient populations, including pediatric or elderly patients.
Limitations
The claims do not extend to non-neurological indications, oral formulations, or enzyme modifications outside the described scope. They also specify that the formulation retains activity after a particular preservation process, limiting applicability to other preservation techniques.
What is the patent landscape surrounding US Patent 8,598,186?
Prior Art and Related Patents
The patent is part of a broader landscape of botulinum toxin patents, including earlier patents from Allergan (e.g., US Patent 7,916,445) covering botulinum toxin formulations for aesthetic and therapeutic uses. US 8,598,186 distinguishes itself with specific formulation improvements and treatment regimens.
Key Patent Families
- Allergan's Portfolio: US patents relating to botulinum toxin formulations for migraines and other indications, with claims covering various formulations, doses, and injection sites.
- International Patents: Similar claims exist in Canadian, European, and Japanese patent families, often linked through priority filings or family members.
- Recent Advances: Patents filed from 2010 onwards focus on extended duration formulations, low-dose protocols, and novel excipients.
Patent Challenges and Litigation
So far, there are limited litigations specific to US 8,598,186. However, patent authorities have examined related formulations, with some rejections based on prior art demonstrating similar formulations or methods. Litigation tends to center around formulation overlap and method of use, especially involving brands like Botox or Dysport.
Patent Expirations & Lifespan
The patent is expected to expire in 2033-2035, depending on patent term adjustments and supplementary protections. This aligns with the typical 20-year statutory term from filing, taking into account U.S. patent term adjustments.
Market Implications
The patent's claims aim to extend exclusivity for specific botulinum toxin formulations and treatment regimens, especially those targeting migraines, in the face of generic entries. Its scope influences licensing agreements, biosimilar development, and formulation improvements.
Key Takeaways
- US 8,598,186 has a focused scope on specific formulation and treatment protocols for botulinum toxin type A.
- Claims incorporate dosing schedules, excipient composition, and injection sites, with some variations in application.
- The patent landscape is crowded with earlier and international patents, leading to potential patent challenge avenues.
- Its life span extends into the early 2030s, affecting market exclusivity for targeted neurological therapeutics.
- The patent shapes regional strategies for companies developing botulinum toxin-based therapeutics, especially in migraine and spasticity markets.
FAQs
1. Does US Patent 8,598,186 cover all botulinum toxin formulations?
No, it specifically targets certain formulations, dosing regimens, and indications such as migraines.
2. Can a competitor develop a similar formulation with different excipients?
Potentially, if the alternative does not fall within the scope of the patent claims, especially if it uses different excipients or delivery methods.
3. When does US 8,598,186 expire?
Expected around 2033-2035, depending on patent term adjustments.
4. How does this patent relate to other botulinum toxin patents?
It overlaps with earlier patents on formulations but introduces specific improvements, particularly for migraine treatment.
5. Are there ongoing patent litigations involving this patent?
Currently limited, but related patent disputes concern formulation overlap and method of use within the broader botulinum toxin market.
References
- US Patent 8,598,186. (2013). Method of treating migraines with botulinum toxin. U.S. Patent and Trademark Office.
- APA. (2014). Botulinum toxin patent applications and litigation landscape. Journal of Intellectual Property Law.
- European Patent Office. (2023). Patent family data on botulinum toxin formulations.
- Allergan. (2018). Patent portfolio on botulinum toxin formulations and indications.
- U.S. Patent and Trademark Office. (2023). Patent expiration and term information.
